BioNTech Says 'We Welcome The European Patent Office's Decision To Revoke Moderna's European Patent 3 718 565 B1; We Believe That This And Others Of Moderna's Patents Do Not Meet The Requirements For Grant And Should Never Have Been Granted'
Portfolio Pulse from Benzinga Newsdesk
BioNTech has welcomed the European Patent Office's decision to revoke Moderna's European patent EP 3 718 565 B1, stating that this patent and others held by Moderna do not meet the necessary requirements for grant and should not have been granted.
November 21, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's position against Moderna's patent may strengthen its competitive stance if it leads to fewer legal barriers and potential licensing fees for its own products.
The revocation of Moderna's patent could potentially reduce legal challenges or licensing costs for BioNTech, which may positively influence its stock price in the short term as the market perceives a more favorable competitive environment.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
The revocation of Moderna's European patent could pose challenges for the company, potentially affecting its ability to protect its intellectual property and its revenue from patented technologies.
The decision by the European Patent Office to revoke one of Moderna's patents could lead to concerns about the strength of its patent portfolio, which may negatively impact investor confidence and Moderna's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80